Fig. 4
From: CD133 significance in glioblastoma development: in silico and in vitro study
The annexin V/PI assay for evaluating the apoptosis rate of U87MG cells. A the annexin V/PI of the control group, B the annexin V/PI of the CD133 silenced group, C the annexin V/PI of the temozolomide-treated group, D the annexin V/PI of the combined treatment group, E the apoptosis rates of studied groups, and F the mRNA expression of BCL2 in different studied groups. CD133 silencing increases the apoptosis rate of U87MG cells and potentiates the anti-tumoral effect of temozolomide on the apoptosis of U87MG cells. CD133 silencing downregulates BCL2 expression in U87MG cells. In the annexin V/PI assay, a lower dose of temozolomide than IC50 was used. *P-value ≤ 0.05, and ****P-value ≤ 0.0001